Were also supported by the report that LDL receptor deficient mice rendered chimeric by transplantation of bone marrow from BAFFR deficient mice also displayed reduced atherosclerosis [13]. The established atherogenicity of B2 cells stands in stark contrast to that of innate-like B1a cells that we have reported to be atheroprotective by the secretion of natural IgM that scavenges apoptotic cells [14]. We have reviewed the contrasting properties of atherogenic B2 cells to those of atheroprotective B1a cells [14,15]. BAFF is widely expressed by immune cells, primarily macrophages and dendritic cells and binds to 3 receptors, BCMA (B-cell maturation antigen/TNFRSF17), TACI (transmembrane activator and calcium-modulator and cyclophilin ligand interactor; TNFRSF13B) and BAFFR (BAFF-receptor; TNFRSF13C) [16]. Whilst BCMA and TACI is differentially expressed on different B cell subsets, BAFFR is expressed by all immature and mature B cells with highest expression in mature B cells [17]. BAFFR expression in mice and in humans correlates 
with positive selection of immature B cells [18]. BAFFR is an appealing therapeutic target to selectively deplete mature B2 cells in B- cell targeted Z-360 web therapy because in contrast to BCMA and TACI that bind both BAFF and its homolog APRIL, BAFFR binds exclusively to BAFF. The report that a single injection of BAFFR monoclonal antibody that prevents BAFF binding drastically reduced mature B cells without affecting B1a cells [19] prompted us to explore the therapeutic potential of this monoclonal antibody to BAFFR to attenuate atherosclerosis in the hyperlipidemic ApoE2/2 mouse. Using this approach we found that anti-BAFFR monoclonal antibody prevented atherosclerosis development and also ameliorated the progression of established atherosclerosis. This novel therapeutic strategy specifically targeting B2 cells in atherosclerosis may have potential for clinical translation.ApoE2/2 mice at the start of 8 week-HFD, and in the intervention study, mice were fed a HFD for 6 weeks to generate atherosclerosis, followed by antibody treatment for a further 6 weeks to MedChemExpress ML 281 investigate therapeutic potential of the antibody in established atherosclerosis. At the end of experiment, mice were euthanized in slow-filled carbon dioxide chamber for three minutes and after assessing lack of respiration and faded eye colour to confirm unconsciousness blood was extracted by cardiac puncture in EDTA-containing syringes.Tissue CollectionPlasma were separated and kept in a -80C freezer for lipid and immunoglobulin analyses. Blood, peritoneal 1516647 fluid, peripheral lymph nodes (inguinal and auxillary) and spleens were processed into single cell suspensions for FACS analysis. The aortic arch and thoracic aorta were snap-frozen in liquid nitrogen and kept in a 280uC freezer for mRNA expression analysis. Aortic roots and spleen were embedded in OCT medium (Tissue-Tek) and kept at 280uC for subsequent atherosclerosis assessment and immunohistochemical analysis.Lymphocyte AssessmentThe following fluorochrome-conjugated anti-mouse antibodies were used: anti-CD22 (PE; BD Biosciences), anti-CD5 (APC; BD Biosciences), anti-CD11b (APC-Cy7; BD Biosciences), anti-CD93 (PE-Cy7; BD Biosciences), anti-CD4 (Pacific Blue; Invitrogen), anti-CD8 (PerCP; BD Biosciences), anti-NK1.1 (PE-Cy7, BD Biosciences), anti-TCRb (FITC; BD Biosciences), anti-CD25 (APC-Cy7; BD Biosciences), anti-foxp3 (PE; eBioscience). Cells isolated from blood, peritoneal fluid, peripheral lymph no.Were also supported by the report that LDL receptor deficient mice rendered chimeric by transplantation of bone marrow from BAFFR deficient mice also displayed reduced atherosclerosis [13]. The established atherogenicity of B2 cells stands in stark contrast to that of innate-like B1a cells that we have reported to be atheroprotective by the secretion of natural IgM that scavenges apoptotic cells [14]. We have reviewed the contrasting properties of atherogenic B2 cells to those of atheroprotective B1a cells [14,15]. BAFF is widely expressed by immune cells, primarily macrophages and dendritic cells and binds to 3 receptors, BCMA (B-cell maturation antigen/TNFRSF17), TACI (transmembrane activator and calcium-modulator and cyclophilin ligand interactor; TNFRSF13B) and BAFFR (BAFF-receptor; TNFRSF13C) [16]. Whilst BCMA and TACI is differentially expressed on different B cell subsets, BAFFR is expressed by all immature and mature B cells with highest expression in mature B cells [17]. BAFFR expression in mice and in humans correlates with positive selection of immature B cells [18]. BAFFR is an appealing therapeutic target to selectively deplete mature B2 cells in B- cell targeted therapy because in contrast 
to BCMA and TACI that bind both BAFF and its homolog APRIL, BAFFR binds exclusively to BAFF. The report that a single injection of BAFFR monoclonal antibody that prevents BAFF binding drastically reduced mature B cells without affecting B1a cells [19] prompted us to explore the therapeutic potential of this monoclonal antibody to BAFFR to attenuate atherosclerosis in the hyperlipidemic ApoE2/2 mouse. Using this approach we found that anti-BAFFR monoclonal antibody prevented atherosclerosis development and also ameliorated the progression of established atherosclerosis. This novel therapeutic strategy specifically targeting B2 cells in atherosclerosis may have potential for clinical translation.ApoE2/2 mice at the start of 8 week-HFD, and in the intervention study, mice were fed a HFD for 6 weeks to generate atherosclerosis, followed by antibody treatment for a further 6 weeks to investigate therapeutic potential of the antibody in established atherosclerosis. At the end of experiment, mice were euthanized in slow-filled carbon dioxide chamber for three minutes and after assessing lack of respiration and faded eye colour to confirm unconsciousness blood was extracted by cardiac puncture in EDTA-containing syringes.Tissue CollectionPlasma were separated and kept in a -80C freezer for lipid and immunoglobulin analyses. Blood, peritoneal 1516647 fluid, peripheral lymph nodes (inguinal and auxillary) and spleens were processed into single cell suspensions for FACS analysis. The aortic arch and thoracic aorta were snap-frozen in liquid nitrogen and kept in a 280uC freezer for mRNA expression analysis. Aortic roots and spleen were embedded in OCT medium (Tissue-Tek) and kept at 280uC for subsequent atherosclerosis assessment and immunohistochemical analysis.Lymphocyte AssessmentThe following fluorochrome-conjugated anti-mouse antibodies were used: anti-CD22 (PE; BD Biosciences), anti-CD5 (APC; BD Biosciences), anti-CD11b (APC-Cy7; BD Biosciences), anti-CD93 (PE-Cy7; BD Biosciences), anti-CD4 (Pacific Blue; Invitrogen), anti-CD8 (PerCP; BD Biosciences), anti-NK1.1 (PE-Cy7, BD Biosciences), anti-TCRb (FITC; BD Biosciences), anti-CD25 (APC-Cy7; BD Biosciences), anti-foxp3 (PE; eBioscience). Cells isolated from blood, peritoneal fluid, peripheral lymph no.
